|
US4281061A
(en)
|
1979-07-27 |
1981-07-28 |
Syva Company |
Double antibody for enhanced sensitivity in immunoassay
|
|
US6018030A
(en)
|
1986-11-04 |
2000-01-25 |
Protein Polymer Technologies, Inc. |
Peptides comprising repetitive units of amino acids and DNA sequences encoding the same
|
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
|
AU638762B2
(en)
|
1989-10-05 |
1993-07-08 |
Optein Inc |
Cell-free synthesis and isolation of novel genes and polypeptides
|
|
US6172197B1
(en)
|
1991-07-10 |
2001-01-09 |
Medical Research Council |
Methods for producing members of specific binding pairs
|
|
ATE414768T1
(de)
|
1991-04-10 |
2008-12-15 |
Scripps Research Inst |
Bibliotheken heterodimerer rezeptoren mittels phagemiden
|
|
PT1024191E
(pt)
|
1991-12-02 |
2008-12-22 |
Medical Res Council |
Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
|
|
DE69329877T2
(de)
|
1992-05-07 |
2001-04-26 |
Affitech A/S, Oslo |
Von L Protein abgeleitete Immunoglobulin-bindende Proteine und deren anwendungen
|
|
WO1994012520A1
(en)
|
1992-11-20 |
1994-06-09 |
Enzon, Inc. |
Linker for linked fusion polypeptides
|
|
US5643763A
(en)
|
1994-11-04 |
1997-07-01 |
Genpharm International, Inc. |
Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating
|
|
US5686292A
(en)
|
1995-06-02 |
1997-11-11 |
Genentech, Inc. |
Hepatocyte growth factor receptor antagonist antibodies and uses thereof
|
|
US5691157A
(en)
|
1995-10-24 |
1997-11-25 |
The Research Foundation Of State University Of New York |
Method for detecting a mammal's prior exposure to radiation or radiomimetic chemicals
|
|
US5846456A
(en)
|
1996-01-17 |
1998-12-08 |
National Science Council |
Method of making gradient index optical element
|
|
EP1958962A3
(en)
|
1997-06-12 |
2013-05-01 |
Novartis International Pharmaceutical Ltd. |
Artificial antibody polypeptides
|
|
US6670127B2
(en)
|
1997-09-16 |
2003-12-30 |
Egea Biosciences, Inc. |
Method for assembly of a polynucleotide encoding a target polypeptide
|
|
PT1015576E
(pt)
|
1997-09-16 |
2005-09-30 |
Egea Biosciences Llc |
Metodo para a sintese quimica completa e montagem de genes e de genomas
|
|
US6846655B1
(en)
|
1998-06-29 |
2005-01-25 |
Phylos, Inc. |
Methods for generating highly diverse libraries
|
|
US7115396B2
(en)
|
1998-12-10 |
2006-10-03 |
Compound Therapeutics, Inc. |
Protein scaffolds for antibody mimics and other binding proteins
|
|
US6818418B1
(en)
|
1998-12-10 |
2004-11-16 |
Compound Therapeutics, Inc. |
Protein scaffolds for antibody mimics and other binding proteins
|
|
DK1137941T4
(da)
|
1998-12-10 |
2014-01-06 |
Brystol Myers Squibb Company |
Protein-scaffolds til antistof-mimetika og andre bindingsproteiner
|
|
US6472147B1
(en)
|
1999-05-25 |
2002-10-29 |
The Scripps Research Institute |
Methods for display of heterodimeric proteins on filamentous phage using pVII and pIX, compositions, vectors and combinatorial libraries
|
|
PL354286A1
(en)
|
1999-08-23 |
2003-12-29 |
Dana-Farber Cancer Institutedana-Farber Cancer Institute |
Pd-1, a receptor for b7-4, and uses therefor
|
|
DK1234031T3
(en)
|
1999-11-30 |
2017-07-03 |
Mayo Foundation |
B7-H1, AN UNKNOWN IMMUNE REGULATORY MOLECULE
|
|
US20130226834A1
(en)
|
2000-04-27 |
2013-08-29 |
Networth Services, Inc. |
Systems and methods for determining the financial status of bonds
|
|
EP1320599A2
(en)
|
2000-06-28 |
2003-06-25 |
Genetics Institute, LLC |
Pd-l2 molecules: pd-1 ligands and uses therefor
|
|
EP2141243A3
(en)
|
2000-10-16 |
2010-01-27 |
Brystol-Myers Squibb Company |
Protein scaffolds for antibody mimics and other binding proteins
|
|
US7794710B2
(en)
|
2001-04-20 |
2010-09-14 |
Mayo Foundation For Medical Education And Research |
Methods of enhancing T cell responsiveness
|
|
EP1283053A1
(en)
|
2001-08-09 |
2003-02-12 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Inhibitors of HER3 activity
|
|
GB0119476D0
(en)
|
2001-08-09 |
2001-10-03 |
Novartis Forschungsstiftlung Z |
Anti-tumour agents and method of identifying anti-tumour agents
|
|
JP4602614B2
(ja)
|
2001-09-26 |
2010-12-22 |
アイシン精機株式会社 |
自動車用ドア
|
|
WO2003037365A1
(en)
|
2001-11-01 |
2003-05-08 |
The Johns Hopkins University |
Methods and compositions for treating vascular leak using hepatocyte growth factor
|
|
WO2003104418A2
(en)
|
2002-06-06 |
2003-12-18 |
Research Corporation Technologies, Inc. |
Reconstituted polypeptides
|
|
DK1534830T3
(da)
|
2002-09-06 |
2011-02-14 |
Isogenica Ltd |
In vito-peptid-ekspressionsbibliotek
|
|
WO2004029224A2
(en)
|
2002-09-30 |
2004-04-08 |
Compound Therapeutics, Inc. |
Methods of engineering spatially conserved motifs in polypeptides
|
|
AU2003295600A1
(en)
*
|
2002-11-14 |
2004-06-15 |
Dharmacon, Inc. |
Functional and hyperfunctional sirna
|
|
EP1578801A2
(en)
|
2002-12-27 |
2005-09-28 |
Domantis Limited |
Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
|
|
WO2004093892A2
(en)
|
2003-04-16 |
2004-11-04 |
Genentech, Inc. |
Stanniocalcin-1, variant or antagonists thereof for selective modulation of vascularization
|
|
WO2005018534A2
(en)
|
2003-05-16 |
2005-03-03 |
Rosetta Inpharmatics, Llc |
Methods and compositions for rna interference
|
|
EP1661905B9
(en)
|
2003-08-28 |
2012-12-19 |
IMANISHI, Takeshi |
Novel artificial nucleic acids of n-o bond crosslinkage type
|
|
US7288638B2
(en)
|
2003-10-10 |
2007-10-30 |
Bristol-Myers Squibb Company |
Fully human antibodies against human 4-1BB
|
|
CN1926551B
(zh)
|
2003-10-27 |
2010-06-16 |
罗斯塔生化科技有限责任公司 |
用于基因沉默的siRNA的设计方法
|
|
EP1711196A4
(en)
|
2003-12-05 |
2011-09-14 |
Bristol Myers Squibb Co |
INHIBITORS OF TYPE-2 VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTORS
|
|
US20080220049A1
(en)
|
2003-12-05 |
2008-09-11 |
Adnexus, A Bristol-Myers Squibb R&D Company |
Compositions and methods for intraocular delivery of fibronectin scaffold domain proteins
|
|
US20060040278A1
(en)
|
2004-01-27 |
2006-02-23 |
Cojocaru Gad S |
Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of ovarian cancer
|
|
EP3042964A1
(en)
|
2004-06-04 |
2016-07-13 |
Genentech, Inc. |
Egfr mutations
|
|
US7736647B2
(en)
|
2005-06-15 |
2010-06-15 |
Monoclonal Antibodies Therapeutics |
Anti-CD71 monoclonal antibodies and uses thereof for treating malignant tumor cells
|
|
PT1907424E
(pt)
|
2005-07-01 |
2015-10-09 |
Squibb & Sons Llc |
Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
|
|
EP1938104A2
(en)
*
|
2005-10-17 |
2008-07-02 |
Institute for Systems Biology |
Tissue-and serum-derived glycoproteins and methods of their use
|
|
EP2441838A3
(en)
|
2006-01-24 |
2013-07-10 |
Domantis Limited |
Fusion proteins that contain natural junctions
|
|
SG134283A1
(en)
|
2006-01-24 |
2007-08-29 |
Ind Tech Res Inst |
Biomarkers for liver fibrotic injury
|
|
RU2429014C2
(ru)
|
2006-03-31 |
2011-09-20 |
Массачусетс Инститьют Оф Текнолоджи |
Лечение опухолей, экспрессирующих мутантные рецепторы egf
|
|
FR2903987B1
(fr)
|
2006-07-21 |
2012-12-21 |
Centre Nat Rech Scient |
Nouveaux derives de cyclodextrines amphiphiles, leur utilisation dans les domaines pharmaceutiques,cosmetiques, alimentaires et leur application a la production de nouveaux nanosystemes
|
|
MX2009005466A
(es)
|
2006-11-22 |
2009-08-17 |
Adnexus A Bristol Myers Sqibb |
Terapeuticos dirigidos a base de proteinas manipuladas para receptores de tirosina cinasas, incluyendo receptor de factor de crecimiento tipo insulina-i.
|
|
WO2008079973A2
(en)
|
2006-12-21 |
2008-07-03 |
Centocor, Inc. |
Egfr binding peptides and uses thereof
|
|
JP2010523595A
(ja)
|
2007-04-04 |
2010-07-15 |
マサチューセッツ インスティテュート オブ テクノロジー |
ポリ（アミノ酸）ターゲッティング部分
|
|
AU2008239594B2
(en)
|
2007-04-13 |
2013-10-24 |
Beth Israel Deaconess Medical Center |
Methods for treating cancer resistant to ErbB therapeutics
|
|
EP2144930A1
(en)
|
2007-04-18 |
2010-01-20 |
ZymoGenetics, Inc. |
Single chain fc, methods of making and methods of treatment
|
|
ES2310122B1
(es)
|
2007-04-20 |
2009-10-30 |
Instituto Cientifico Y Tecnologico De Navarra, S.A |
Nanoparticulas que comprenden una ciclodextrina y una molecula biologicamente activa y sus aplicaciones.
|
|
US20090042906A1
(en)
|
2007-04-26 |
2009-02-12 |
Massachusetts Institute Of Technology |
Methods for treating cancers associated with constitutive egfr signaling
|
|
WO2008156642A1
(en)
|
2007-06-15 |
2008-12-24 |
Vasgene Therapeutics, Inc. |
Non-immunoglobulin antigen binding scaffolds for inhibiting angiogenesis and tumor growth
|
|
US8470966B2
(en)
|
2007-08-10 |
2013-06-25 |
Protelica, Inc. |
Universal fibronectin type III binding-domain libraries
|
|
WO2009023184A2
(en)
|
2007-08-10 |
2009-02-19 |
Protelix, Inc. |
Universal fibronectin type iii binding-domain libraries
|
|
CA2700410C
(en)
|
2007-10-03 |
2020-10-06 |
Cornell University |
Treatment of proliferative disorders using antibodies to psma
|
|
US8633297B2
(en)
|
2007-10-31 |
2014-01-21 |
Medimmune, Llc |
Protein scaffolds
|
|
WO2009073809A2
(en)
|
2007-12-04 |
2009-06-11 |
Alnylam Pharmaceuticals, Inc. |
Carbohydrate conjugates as delivery agents for oligonucleotides
|
|
WO2009085468A2
(en)
|
2007-12-19 |
2009-07-09 |
Centocor, Inc. |
Engineered phage vectors for the design and the generation of a human non-antibody peptide or protein phage library via fusion to pix of m13 phage
|
|
AU2008343589A1
(en)
|
2007-12-19 |
2009-07-09 |
Centocor Ortho Biotech Inc. |
Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods
|
|
EP2238247A2
(en)
|
2007-12-19 |
2010-10-13 |
Centocor Ortho Biotech Inc. |
Alternative scaffold protein fusions phage display via fusion to plx of m13 phage
|
|
WO2009083804A2
(en)
|
2007-12-27 |
2009-07-09 |
Novartis Ag |
Improved fibronectin-based binding molecules and their use
|
|
AU2009213141A1
(en)
|
2008-02-14 |
2009-08-20 |
Bristol-Myers Squibb Company |
Targeted therapeutics based on engineered proteins that bind EGFR
|
|
KR20100135780A
(ko)
|
2008-03-06 |
2010-12-27 |
제넨테크, 인크. |
Ｃ-ｍｅｔ 및 ｅｇｆｒ 길항제로의 조합 요법
|
|
CL2009000843A1
(es)
|
2008-04-11 |
2009-07-24 |
Galaxy Biotech Llc |
Metodo para tratar cancer en un paciente que comprende la administracion de un primer agente que es inhibidor de factor de crecimiento de hepatocito (hgf) en combinacion con un segundo agente que es inhibidor de una ruta de senalizacion celular diferente de la ruta hgf/cmet.
|
|
EA201001734A1
(ru)
|
2008-05-02 |
2011-10-31 |
Новартис Аг |
Улучшенные связывающие молекулы на основе фибронектина и их применение
|
|
UY31800A
(es)
|
2008-05-05 |
2009-11-10 |
Smithkline Beckman Corp |
Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
|
|
WO2009142773A2
(en)
|
2008-05-22 |
2009-11-26 |
Bristol-Myers Squibb Company |
Multivalent fibronectin based scaffold domain proteins
|
|
US8552154B2
(en)
|
2008-09-26 |
2013-10-08 |
Emory University |
Anti-PD-L1 antibodies and uses therefor
|
|
EP2352765B1
(en)
|
2008-10-01 |
2018-01-03 |
Amgen Research (Munich) GmbH |
Cross-species-specific single domain bispecific single chain antibody
|
|
JP2012504606A
(ja)
|
2008-10-01 |
2012-02-23 |
ラディック インスティテュート フォー キャンサー リサーチ |
癌の治療方法
|
|
EP2349327A4
(en)
|
2008-10-23 |
2012-11-28 |
Massachusetts Inst Technology |
COMMITMENT DIRECTED FC RECEIVERS ACTIVATORS
|
|
ES2705714T3
(es)
|
2008-10-31 |
2019-03-26 |
Janssen Biotech Inc |
Métodos y usos de dominio de Fibronectina tipo III basado en estructuras de composiciones
|
|
US8415291B2
(en)
|
2008-10-31 |
2013-04-09 |
Centocor Ortho Biotech Inc. |
Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses
|
|
PA8849001A1
(es)
|
2008-11-21 |
2010-06-28 |
Lilly Co Eli |
Anticuerpos de c-met
|
|
TWI496582B
(zh)
|
2008-11-24 |
2015-08-21 |
必治妥美雅史谷比公司 |
雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子
|
|
US8545839B2
(en)
|
2008-12-02 |
2013-10-01 |
Pierre Fabre Medicament |
Anti-c-Met antibody
|
|
EP3255060A1
(en)
|
2008-12-09 |
2017-12-13 |
F. Hoffmann-La Roche AG |
Anti-pd-l1 antibodies and their use to enhance t-cell function
|
|
JP5844159B2
(ja)
|
2009-02-09 |
2016-01-13 |
ユニヴェルシテ デクス−マルセイユＵｎｉｖｅｒｓｉｔｅ Ｄ’Ａｉｘ−Ｍａｒｓｅｉｌｌｅ |
Ｐｄ−１抗体およびｐｄ−ｌ１抗体ならびにその使用
|
|
BRPI1008532B1
(pt)
|
2009-02-12 |
2021-12-14 |
Janssen Biotech, Inc |
Arcabouço de proteína isolada, método para construção de uma biblioteca de arcabouço de proteína isolada, molécula de ácido nucleico isolada, vetor de ácido nucleico isolado, célula hospedeira de bactéria ou fungo, composição, dispositivo médico e artigo de manufatura para uso farmacêutico ou de diagnóstico em seres humanos
|
|
WO2010115202A2
(en)
|
2009-04-03 |
2010-10-07 |
Dicerna Pharmaceuticals, Inc. |
Methods and compositions for the specific inhibition of kras by blunt ended double-stranded rna
|
|
CN103555722B
(zh)
|
2009-04-03 |
2016-08-31 |
戴瑟纳制药公司 |
利用不对称双链rna特异性抑制kras的方法和组合物
|
|
EP2417164A1
(en)
|
2009-04-07 |
2012-02-15 |
Roche Glycart AG |
Bispecific anti-erbb-2/anti-c-met antibodies
|
|
EP2452165A1
(en)
|
2009-07-07 |
2012-05-16 |
Siemens AG |
Apparatus and method for measuring multi-phase fluid flow
|
|
WO2011020033A2
(en)
|
2009-08-13 |
2011-02-17 |
Massachusetts Institute Of Technology |
Engineered proteins including mutant fibronectin domains
|
|
KR101237036B1
(ko)
*
|
2009-11-04 |
2013-02-25 |
성균관대학교산학협력단 |
안티센스 가닥에 의한 오프-타겟 효과를 최소화한 신규한 ｓｉＲＮＡ 구조 및 그 용도
|
|
PL2504364T3
(pl)
|
2009-11-24 |
2017-12-29 |
Medimmune Limited |
Ukierunkowane środki wiążące przeciwko B7-H1
|
|
WO2011100700A2
(en)
|
2010-02-12 |
2011-08-18 |
University Of Rochester |
Antigenic mimics of discontinuous epitopes of pathogen recognized by broadly neutralizing antibodies
|
|
PT3904391T
(pt)
|
2010-03-10 |
2024-10-14 |
Genmab As |
Anticorpos monoclonais contra c-met
|
|
WO2011130324A1
(en)
|
2010-04-13 |
2011-10-20 |
Medimmune, Llc |
Fibronectin type iii domain-based multimeric scaffolds
|
|
HRP20241208T1
(hr)
|
2010-04-20 |
2024-11-22 |
Genmab A/S |
Heterodimerni proteini koji sadrže fc fragment protutijela i postupci za njihovu proizvodnju
|
|
KR101860963B1
(ko)
|
2010-04-23 |
2018-05-24 |
제넨테크, 인크. |
이종다량체 단백질의 생산
|
|
US8569227B2
(en)
|
2010-04-30 |
2013-10-29 |
Janssen Biotech, Inc. |
Stabilized fibronectin domain compositions, methods and uses
|
|
JP6023703B2
(ja)
|
2010-05-26 |
2016-11-09 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
改善された安定性を有するフィブロネクチンをベースとする足場タンパク質
|
|
CN107903321A
(zh)
|
2010-07-30 |
2018-04-13 |
诺华有限公司 |
纤连蛋白摇篮分子和其库
|
|
EP2621953B1
(en)
|
2010-09-30 |
2017-04-05 |
Ablynx N.V. |
Biological materials related to c-met
|
|
US20130273561A1
(en)
|
2010-10-29 |
2013-10-17 |
The Governing Council Of The University Of Toronto |
Lipid encapsulation of surface enhanced raman scattering (sers) nanoparticles
|
|
WO2012162418A1
(en)
|
2011-05-23 |
2012-11-29 |
The University Of North Carolina At Chapel Hill |
Methods and compositions for heterodimeric targeting ligands
|
|
US20120321666A1
(en)
|
2011-05-23 |
2012-12-20 |
Cooper Laurence J N |
T cell therapy for b cell lymphoma
|
|
US20120315639A1
(en)
|
2011-06-08 |
2012-12-13 |
Glenn Yaguang Deng |
Method and apparatus for single cell isolation and analysis
|
|
JP6440496B2
(ja)
|
2011-09-27 |
2018-12-19 |
ヤンセン バイオテツク，インコーポレーテツド |
選択的結合表面を有するフィブロネクチンｉｉｉ型反復ベースのタンパク質スカフォールド
|
|
KR101764096B1
(ko)
|
2011-11-28 |
2017-08-02 |
메르크 파텐트 게엠베하 |
항-ｐｄ-ｌ1 항체 및 그의 용도
|
|
AU2012358238B2
(en)
|
2011-12-22 |
2017-12-07 |
C. Frank Bennett |
Methods for modulating Metastasis-Associated-in-Lung-Adenocarcinoma-Transcript-1(MALAT-1) expression
|
|
JP6060178B2
(ja)
|
2012-01-05 |
2017-01-18 |
バイオニア コーポレーションＢｉｏｎｅｅｒ Ｃｏｒｐｏｒａｔｉｏｎ |
高効率のナノ粒子型二本鎖オリゴｒｎａ構造体およびその製造方法
|
|
HK1203971A1
(en)
|
2012-05-15 |
2015-11-06 |
Bristol-Myers Squibb Company |
Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
|
|
EP2852380A4
(en)
|
2012-05-23 |
2016-01-20 |
Univ Ohio State |
LIPID-COATED ALBUMIN NANOPARTICLE COMPOSITIONS AND METHOD FOR THE PREPARATION AND METHOD OF USE THEREOF
|
|
CN104470944B
(zh)
|
2012-05-25 |
2021-09-14 |
詹森生物科技公司 |
非天然共有白蛋白结合结构域
|
|
KR20220084444A
(ko)
|
2012-05-31 |
2022-06-21 |
소렌토 쎄라퓨틱스, 인코포레이티드 |
Pd-l1에 결합하는 항원 결합 단백질
|
|
CN111499755A
(zh)
|
2012-08-03 |
2020-08-07 |
丹娜法伯癌症研究院 |
抗-pd-l1和pd-l2双结合抗体单一试剂及其使用方法
|
|
WO2014025828A1
(en)
|
2012-08-06 |
2014-02-13 |
The Regents Of The University Of California |
Engineered antibody fragments for targeting and imaging cd8 expression in vivo
|
|
BR112015007672A2
(pt)
|
2012-10-04 |
2017-08-08 |
Dana Farber Cancer Inst Inc |
anticorpos anti-pd-l1 monoclonais humanos e métodos de uso
|
|
MX361088B
(es)
|
2012-11-21 |
2018-11-26 |
Janssen Biotech Inc |
Anticuerpos del receptor del factor de crecimiento epidérmico aislado/del receptor del factor de crecimiento de hepatocitos (egfr/c-met) biespecíficos.
|
|
US9695228B2
(en)
|
2012-11-21 |
2017-07-04 |
Janssen Biotech, Inc. |
EGFR and c-Met fibronectin type III domain binding molecules
|
|
AR093984A1
(es)
|
2012-12-21 |
2015-07-01 |
Merck Sharp & Dohme |
Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
|
|
US9433689B2
(en)
|
2013-03-12 |
2016-09-06 |
The Board Of Trustees Of The Leland Stanford Junio |
Probes and methods of imaging non-Hodgkins lymphoma
|
|
WO2014165082A2
(en)
|
2013-03-13 |
2014-10-09 |
Medimmune, Llc |
Antibodies and methods of detection
|
|
EP2968587A2
(en)
|
2013-03-13 |
2016-01-20 |
Bristol-Myers Squibb Company |
Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto
|
|
EP3594240B1
(en)
|
2013-05-20 |
2023-12-06 |
F. Hoffmann-La Roche AG |
Anti-transferrin receptor antibodies and methods of use
|
|
US20160145355A1
(en)
|
2013-06-24 |
2016-05-26 |
Biomed Valley Discoveries, Inc. |
Bispecific antibodies
|
|
WO2015048724A1
(en)
|
2013-09-30 |
2015-04-02 |
The University Of North Carolina At Chapel Hill |
Methods and compositions for self-assembly system of nanoparticles and microparticles for multi-targeting specificity
|
|
BR112016008125B1
(pt)
|
2013-10-14 |
2023-11-21 |
Janssen Biotech, Inc. |
Domínio proteico isolado de fibronectina tipo iii modificado com cisteína, seu método de produção e método para produzir uma molécula isolada de de fibronectina tipo iii biespecífica modificada com cisteína
|
|
EP3060581A4
(en)
|
2013-10-25 |
2017-06-07 |
Dana-Farber Cancer Institute, Inc. |
Anti-pd-l1 monoclonal antibodies and fragments thereof
|
|
CA2932819A1
(en)
|
2013-12-09 |
2015-06-18 |
New York University |
Compositions and methods for phagocyte delivery of anti-staphylococcal agents
|
|
WO2015092393A2
(en)
|
2013-12-17 |
2015-06-25 |
Kymab Limited |
Human targets
|
|
PL3094351T3
(pl)
|
2014-01-15 |
2022-06-27 |
Kadmon Corporation, Llc |
Środki immunomodulujące
|
|
TWI680138B
(zh)
|
2014-01-23 |
2019-12-21 |
美商再生元醫藥公司 |
抗ｐｄ-ｌ１之人類抗體
|
|
ES2736127T3
(es)
|
2014-03-20 |
2019-12-26 |
Bristol Myers Squibb Co |
Dominios de tipo III de fibronectina de unión a seroalbúmina
|
|
AU2015243535A1
(en)
|
2014-04-08 |
2016-11-03 |
University Of Southern California |
Polypeptide compositions with Type VII collagen fibronectin Type Ill- like repeats and treatment methods for wound closure and healing
|
|
JP6666905B2
(ja)
|
2014-05-29 |
2020-03-18 |
スプリング バイオサイエンス コーポレーション |
Ｐｄ−ｌ１抗体及びその使用
|
|
WO2015195163A1
(en)
|
2014-06-20 |
2015-12-23 |
R-Pharm Overseas, Inc. |
Pd-l1 antagonist fully human antibody
|
|
WO2016004043A1
(en)
|
2014-06-30 |
2016-01-07 |
Blend Therapeutics, Inc. |
Targeted conjugates and particles and formulations thereof
|
|
CN106604742B
(zh)
|
2014-07-03 |
2019-01-11 |
百济神州有限公司 |
抗pd-l1抗体及其作为治疗剂及诊断剂的用途
|
|
IL316808A
(en)
|
2014-08-20 |
2025-01-01 |
Alnylam Pharmaceuticals Inc |
Modified double-stranded RNA materials and their uses
|
|
CN107207379B
(zh)
|
2014-11-25 |
2021-08-10 |
百时美施贵宝公司 |
用于生物制品的18f-放射性标记的方法和组合物
|
|
CA2969067A1
(en)
|
2014-11-25 |
2016-06-02 |
Bristol-Myers Squibb Company |
Novel pd-l1 binding polypeptides for imaging
|
|
BR112017023862A2
(pt)
|
2015-05-04 |
2018-07-17 |
Cytomx Therapeutics Inc |
anticorpos anti-cd71, anticorpos anti-cd71 ativáveis, e métodos de uso destes
|
|
EP3291836A4
(en)
|
2015-05-06 |
2018-11-14 |
Janssen Biotech, Inc. |
Prostate specific membrane antigen (psma) bispecific binding agents and uses thereof
|
|
US10844111B2
(en)
|
2015-05-06 |
2020-11-24 |
Janssen Biotech, Inc. |
Prostate specific membrane antigen binding fibronectin type III domains
|
|
JP2018517708A
(ja)
|
2015-06-05 |
2018-07-05 |
ニューヨーク・ユニバーシティ |
抗ブドウ球菌生物学的薬剤のための組成物及び方法
|
|
US10426842B2
(en)
|
2015-07-15 |
2019-10-01 |
The Curators Of The University Of Missouri |
Targeted nanoparticle conjugate and method for co-delivery of siRNA and drug
|
|
JP2019513371A
(ja)
|
2016-04-01 |
2019-05-30 |
アビディティー バイオサイエンシーズ エルエルシー |
核酸ポリペプチド組成物とその使用
|
|
CN105907719B
(zh)
|
2016-04-18 |
2019-10-18 |
阿思科力(苏州)生物科技有限公司 |
Anti ROBO1 CAR-T细胞及其制备和应用
|
|
SG11201810687SA
(en)
|
2016-06-03 |
2018-12-28 |
Janssen Biotech Inc |
Serum albumin-binding fibronectin type iii domains
|
|
AU2017286811A1
(en)
*
|
2016-06-17 |
2018-11-22 |
Ionis Pharmaceuticals, Inc. |
Modulation of gys1 expression
|
|
DK3473270T5
(da)
*
|
2016-06-20 |
2024-09-09 |
Genahead Bio Inc |
Konjugat af antistof-lægemiddel
|
|
MA45412A
(fr)
|
2016-06-21 |
2021-05-26 |
Janssen Biotech Inc |
Molécules de liaison au domaine de fibronectine de type iii modifiées par la cystéine
|
|
MA46236A
(fr)
|
2016-09-14 |
2019-07-24 |
Janssen Biotech Inc |
Récepteurs antigéniques chimériques comprenant des domaines de la fibronectine de type iii spécifiques du bcma, et utilisations correspondantes
|
|
CN110225770B
(zh)
|
2016-12-14 |
2022-04-26 |
杨森生物科技公司 |
结合cd8a的纤连蛋白iii型结构域
|
|
EP3554535A4
(en)
|
2016-12-14 |
2020-10-21 |
Janssen Biotech, Inc. |
PD-L1 BINDING FIBRONECTIN TYPE III DOMAINS
|
|
EP3554561B1
(en)
|
2016-12-14 |
2023-06-28 |
Janssen Biotech, Inc. |
Cd137 binding fibronectin type iii domains
|
|
IL268417B2
(en)
*
|
2017-02-10 |
2025-05-01 |
Univ Rockefeller |
Methods for cell-type specific profiling to identify drug targets
|
|
CA3082204A1
(en)
|
2017-12-13 |
2019-06-20 |
Janssen Biotech, Inc. |
Immortalized car-t cells genetically modified to eliminate t-cell receptor and beta 2-microglobulin expression
|
|
US20190184028A1
(en)
*
|
2017-12-14 |
2019-06-20 |
Janssen Biotech, Inc. |
Targeting with firbronectin type iii like domain molecules
|
|
MX2020011570A
(es)
*
|
2018-05-07 |
2020-11-24 |
Alnylam Pharmaceuticals Inc |
Administracion extrahepatica.
|
|
AR115847A1
(es)
*
|
2018-07-25 |
2021-03-03 |
Ionis Pharmaceuticals Inc |
Compuestos y métodos para reducir la expresión de la atxn2
|
|
WO2021030763A1
(en)
|
2019-08-15 |
2021-02-18 |
Ionis Pharmaceuticals, Inc. |
Modified oligomeric compounds and uses thereof
|
|
KR20220062517A
(ko)
|
2019-08-15 |
2022-05-17 |
아이오니스 파마수티컬즈, 인코포레이티드 |
결합 변형된 올리고머 화합물 및 이의 용도
|
|
CN119119240A
(zh)
|
2019-10-14 |
2024-12-13 |
Aro生物疗法公司 |
结合cd71的纤维粘连蛋白iii型结构域
|
|
US11781138B2
(en)
|
2019-10-14 |
2023-10-10 |
Aro Biotherapeutics Company |
FN3 domain-siRNA conjugates and uses thereof
|
|
WO2021226107A1
(en)
|
2020-05-05 |
2021-11-11 |
Avidity Biosciences, Inc. |
Compositions and methods of treating pompe disease
|
|
AU2022239717A1
(en)
|
2021-03-15 |
2023-11-02 |
Maze Therapeutics, Inc. |
Inhibitors of glycogen synthase 1 (gys1) and methods of use thereof
|
|
EP4314016A1
(en)
|
2021-03-31 |
2024-02-07 |
Entrada Therapeutics, Inc. |
Cyclic cell penetrating peptides
|
|
EP4323008A4
(en)
|
2021-04-14 |
2026-02-25 |
Aro Biotherapeutics Company |
FN3-ARNSI DOMAIN CONJUGATES AND THEIR USES
|
|
CA3214552A1
(en)
*
|
2021-04-14 |
2022-10-20 |
Russell C. Addis |
Cd71 binding fibronectin type iii domains
|
|
CN119604311A
(zh)
|
2022-04-14 |
2025-03-11 |
Aro生物疗法公司 |
FN3结构域-siRNA缀合物与酶替代疗法
|
|
EP4519440A2
(en)
|
2022-05-06 |
2025-03-12 |
ARO Biotherapeutics Company |
Compositions and methods for gys1 inhibition
|